 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
Adult:
Initially, 25 mg bid on day 1, increased to 50 mg bid on day 2, 100 mg bid on day 3 and 150 mg bid on day 4. Usual dose range: 300-450 mg daily. Max dose: 750 mg daily.
Elderly: Initially, 25 mg daily, increased in steps of 25-50 mg daily according to response. |
| Max Dosage: 750 mg/day. |
| |
| Oral |
| ACUTE MANIAC EPISODES OF BIPOLAR DISORDER |
| Adult:
Manic phase: 50 mg bid on day 1, 100 mg bid on day 2, 150 mg bid on day 3 and 200 mg bid on day 4. Usual range: 400-800 mg/day; adjust dose according to response. Dosage increments should be ≤200 mg/day. Depressive phase: Initially, 50 mg at bedtime on day 1; 100 mg on day 2, 200 mg on day 3, and 300 mg on day 4. May increase to 400 mg on day 5 and 600 mg on day 8, if needed.
Elderly: Initially, 25 mg daily, increased in steps of 25-50 mg daily according to response. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
CV disease, cerebrovascular disease or conditions that predispose to hypotension. History of seizures; neuroleptic malignant syndrome; tardive dyskinesia. Monitor glycaemic control, especially in diabetics. Hepatic or renal impairment. Gradual withdrawal is recommended. Monitor for signs of clinical worsening, suicidality or unusual changes in behaviour. Pregnancy and lactation. |
| |
|
| Adverse Drug Reactions |
Headache, asthenia, abdominal pain, back pain, fever, chest pain, postural and orthostatic hypotension, hypertension, constipation, dry mouth, dyspepsia, diarrhoea, leucopenia, elevations in serum transaminase level, weight gain, myalgia, somnolence, dizziness, anxiety, rhinitis, rash, dry skin, ear pain, UTI, syncope, neuroleptic malignant syndrome, variations in WBC count, neutropenia, eosinophilia, elevations in nonfasting serum triglyceride level and total cholesterol, decrease in thyroid hormone levels, prolongation of the QTc interval. |
| |
|
| Interactions |
Increased risk of drowsiness and postural hypotension when used with alcohol. CYP3A4 inducers eg. phenytoin and carbamazepine may decrease plasma levels of quetiapine while CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels. |
| |
|
|
|
